CSRC approves Aitake's application for listing on the Shanghai Stock Exchange main board IPO
On February 5th, the China Securities Regulatory Commission issued the "Reply on Approving the Initial Public Offering of Shares by Wuhu E-Tech Automotive Electronics Co., Ltd.".
On February 5th, the China Securities Regulatory Commission released the "Approval of the Initial Public Offering of Shares of Wuhu Aitech Automotive Electronics Co., Ltd.". It is reported that Aitech plans to list on the Shanghai Stock Exchange main board, with Huatai United Securities as its sponsoring institution, aiming to raise 1.5 billion yuan.
The prospectus shows that Aitech is a leading provider of automotive electronic intelligent solutions in the industry, mainly engaged in the research, development, production, and sales of automotive electronic products in the areas of vehicle body, intelligent cockpit, power domain, and intelligent driving domain. It also provides customers with automotive electronic EMS and technology development services.
Since its establishment, the company has always focused on the field of automotive electronics, and has built a complete business system from product research and development design, testing and verification to mass production and delivery. It has formed a product layout covering the four major functional domains of vehicle body, intelligent cockpit, power domain, and intelligent driving domain.
Related Articles

PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc

Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.

Don't be scared by panic! The conflict in the Middle East has created a "golden buying opportunity". Are these two high-yield blue-chip stocks worth investing in with your eyes closed?
PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc

Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.

Don't be scared by panic! The conflict in the Middle East has created a "golden buying opportunity". Are these two high-yield blue-chip stocks worth investing in with your eyes closed?






